8-K: Guardant Health Reports Strong Q4, Full Year 2025 Preliminary Results

Guardant Health announced preliminary unaudited Q4 and full year 2025 results, showing significant revenue and test volume growth driven by oncology and screening.

Summary

• Total revenue for Q4 2025 was approximately $280 million, an increase of 39% compared to the same period in 2024.
• Approximately 79,000 oncology tests were reported in Q4 2025, a 38% increase year-over-year.
• Approximately 38,000 Shield screening tests were reported in Q4 2025, compared to 6,400 in the prior year period.
• Total revenue for the full year 2025 was approximately $981 million, an increase of 33% compared to the full year 2024.
• Approximately 276,000 oncology tests were reported for the full year 2025, a 34% increase year-over-year.
• Approximately 87,000 Shield screening tests were reported for the full year 2025.
• Preliminary unaudited free cash flow was approximately negative $54 million for Q4 2025 and negative $233 million for the full year 2025.
• Cash, cash equivalents, restricted cash, and marketable debt securities were approximately $1.3 billion as of December 31, 2025.
• These results are preliminary and unaudited, subject to change as the company completes its financial statements.

Sentiment

Score: 8

Explanation: The filing reports strong preliminary revenue and test volume growth, indicating robust market adoption and operational success. The expansion of the Shield platform to include multi-cancer detection is a significant positive. However, the company continues to report negative free cash flow, which, while improving, remains a point of attention for long-term profitability.

Positives

• Total revenue increased by 39% in Q4 2025 to approximately $280 million.
• Full year 2025 total revenue grew 33% to approximately $981 million.
• Oncology test volumes increased by 38% in Q4 2025 and 34% for the full year 2025.
• Shield screening tests showed significant growth, reaching approximately 38,000 in Q4 2025 and 87,000 for the full year 2025, compared to 6,400 in the prior year Q4.
• Nearly 100,000 patients have been screened with Shield since FDA approval.
• The Shield platform has been expanded to include multi-cancer detection findings, enhancing its clinical value.
• The company maintains a strong cash position with approximately $1.3 billion in cash, cash equivalents, restricted cash, and marketable debt securities as of December 31, 2025.

Negatives

• Preliminary unaudited free cash flow was negative $54 million for Q4 2025.
• Preliminary unaudited free cash flow was negative $233 million for the full year 2025.

Risks

• The reported financial results for Q4 and full year 2025 are preliminary and unaudited, inherently uncertain, and subject to change as the company completes its financial results.
• There is no assurance that final results for this period will not differ materially from these preliminary estimates.
• During the preparation of consolidated financial statements, independent registered public accountants may identify items that could cause final reported results to be materially different from the preliminary estimates.
• Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from anticipated results and expectations.

Future Outlook

The company expects momentum in its oncology business to continue throughout 2026, driven by pioneering innovation from its Smart Platform and best-in-class commercial execution, with the launch of multiple groundbreaking products. Guardant Health anticipates further advancing the fight against cancer in 2026 and beyond, leveraging Shield's strong momentum and expanded multi-cancer detection findings.

Management Comments

• "2025 was a breakout year for Guardant, with total revenue growth accelerating to 33% year-over-year." Helmy Eltoukhy, co-founder and co-CEO.
• "We saw exceptional volume growth in Oncology over the last year, primarily driven by pioneering innovation from our Smart Platform and best-in-class commercial execution." Helmy Eltoukhy, co-founder and co-CEO.
• "We expect this momentum to continue throughout the year with the launch of multiple groundbreaking products that will fuel the next phase of growth in our Oncology business." Helmy Eltoukhy, co-founder and co-CEO.
• "We are incredibly proud of Shield's strong momentum as we continue to strengthen our leadership in the blood-based colorectal cancer screening market, with Shield positioned as one of the most successful diagnostic launches to date." AmirAli Talasaz, co-founder and co-CEO.
• "Since FDA approval, nearly 100,000 patients have been screened with Shield." AmirAli Talasaz, co-founder and co-CEO.
• "We have now expanded Shield to include multi-cancer detection findings, further enhancing the clinical value of the platform for both patients and physicians." AmirAli Talasaz, co-founder and co-CEO.
• "Together, these milestones will further advance the fight against cancer in 2026 and beyond." AmirAli Talasaz, co-founder and co-CEO.

Industry Context

Guardant Health operates as a leading precision oncology company, aiming to transform patient care and accelerate new cancer therapies. Its strong growth in oncology and the successful launch and expansion of its blood-based colorectal cancer screening product, Shield, position it as a significant player in the rapidly evolving diagnostic and screening market, particularly in liquid biopsy for cancer detection. The expansion of Shield to include multi-cancer detection aligns with a broader industry trend towards earlier and less invasive cancer detection methods.

Comparison to Industry Standards

• The company's 33-39% revenue growth rates are robust, indicating strong market penetration and demand for its precision oncology and screening products, potentially outperforming many established diagnostic companies in the sector.
• The rapid adoption of Shield, with nearly 100,000 patients screened since FDA approval and significant year-over-year test volume increases (from 6,400 to 38,000 in Q4), suggests a highly successful diagnostic launch, comparable to or exceeding the initial uptake of other innovative diagnostic tests in the oncology space.
• The expansion of Shield to multi-cancer detection positions Guardant Health competitively against other companies developing multi-cancer early detection (MCED) tests, such as Grail (Illumina) and Exact Sciences (Cologuard, Oncoguard Liver), by enhancing the clinical value and market potential of its platform.

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue and test volume growth, indicating increasing market share and potential for future profitability, though negative free cash flow warrants attention.
• Customers (Patients & Physicians): Positive impact through expanded access to advanced precision oncology and screening tests, including multi-cancer detection capabilities, potentially leading to improved patient outcomes.
• Employees: Positive impact from company growth and innovation, potentially leading to job security and opportunities.

Next Steps

• Guardant Health will post its presentation for the 2026 J.P. Morgan Healthcare Conference on its website on January 12, 2026.
• The company plans to launch multiple groundbreaking products in its Oncology business throughout 2026.
• Guardant Health plans to report its fourth quarter and full year audited financial results during its February 2026 earnings call.

Key Dates

Recommendation

While the preliminary results show impressive revenue and test volume growth, particularly with the Shield platform, the continued negative free cash flow suggests the company is still in a high-growth, investment-heavy phase. The preliminary nature of the results also introduces a degree of uncertainty until audited financials are released. Investors should hold to monitor the path to profitability and the impact of new product launches, balancing strong top-line growth against ongoing cash burn.

Keywords

precision oncology, cancer screening, liquid biopsy, Guardant Health, GH, oncology tests, Shield, colorectal cancer, multi-cancer detection, financial results, revenue growth, test volume, Q4 2025, full year 2025